{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:56:28Z","timestamp":1763016988732},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T00:00:00Z","timestamp":1258416000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1038\/sj.bjc.6605443","type":"journal-article","created":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T02:07:39Z","timestamp":1258510059000},"page":"19-22","source":"Crossref","is-referenced-by-count":13,"title":["A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma"],"prefix":"10.1038","volume":"102","author":[{"given":"R","family":"Marcus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Aultman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,17]]},"reference":[{"key":"BF6605443_CR1","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.1998.16.7.2339","volume":"16","author":"BF Cole","year":"1998","unstructured":"Cole BF, Solal-Celigny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A (1998) Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 16: 2339\u20132344","journal-title":"J Clin Oncol"},{"key":"BF6605443_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1023\/A:1008806828316","volume":"8","author":"DL Fairclough","year":"1999","unstructured":"Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM (1999) Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8: 723\u2013731","journal-title":"Qual Life Res"},{"key":"BF6605443_CR3","unstructured":"Fayers PM, Machin D (2000) Quality of Life. Assessment, Analysis and Interpretation. Wiley: Chichester, pp xii +404. ISBN 0-471-96861-7"},{"key":"BF6605443_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.0006-341X.2001.00376.x","volume":"57","author":"JP Fine","year":"2001","unstructured":"Fine JP, Gelber RD (2001) Joint regression analysis of survival and quality-adjusted survival. Biometrics 57: 376\u2013382","journal-title":"Biometrics"},{"key":"BF6605443_CR5","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20: 75\u201388","journal-title":"Semin Oncol"},{"key":"BF6605443_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417\u20131423","journal-title":"Blood"},{"key":"BF6605443_CR7","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26: 4579\u20134586","journal-title":"J Clin Oncol"},{"key":"BF6605443_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/annonc\/mdm543","volume":"19","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJ, Rule S, Walker M, Wild D (2008) The impact of follicular lymphoma on health-related quality of life. Ann Oncol 19: 570\u2013576","journal-title":"Ann Oncol"},{"key":"BF6605443_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","volume":"15","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Feeny D, Hunt TL, Cole BF (2006) Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 15: 411\u2013423","journal-title":"Qual Life Res"},{"key":"BF6605443_CR10","first-page":"281","volume-title":"Using the Q-TWiST Method for Treatment Comparisons in Clinical Trials","author":"MJ Staquet","year":"1998","unstructured":"Staquet MJ, Hays RD, Fayers PM (eds) (1998) Using the Q-TWiST Method for Treatment Comparisons in Clinical Trials. Oxford University Press: USA, pp 281\u2013296"},{"key":"BF6605443_CR11","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89: 3909\u20133918","journal-title":"Blood"},{"key":"BF6605443_CR12","volume-title":"Risk Analysis \u2013 A Quantitative Guide","author":"D Vose","year":"2000","unstructured":"Vose D (2000) Risk Analysis \u2013 A Quantitative Guide 2nd edn, John Wiley & Sons: Chichester"},{"key":"BF6605443_CR13","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1200\/JCO.1998.16.8.2834","volume":"16","author":"B Zee","year":"1998","unstructured":"Zee B, Cole B, Li T, Browman G, James K, Johnston D, Sugano D, Pater J (1998) Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 16: 2834\u20132839","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605443","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:43:03Z","timestamp":1684413783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,17]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["BF6605443"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605443","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,17]]}}}